This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Bioventus Surges 103% in Six Months: Is the Stock Worth a Buy?
by Sundeep Ganoria
BVS' stock generates phenomenal returns, driven by double-digit revenue growth across the Pain Treatments and Surgical Solutions franchises.
Medtronic (MDT) Up 0.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ISRG Stock Rallies 14% in 3 Months: Is It Still Worth Buying?
by Indrajit Bandyopadhyay
Intuitive Surgical is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.
The Zacks Analyst Blog Verizon, Prologis, Medtronic and Crimson
by Zacks Equity Research
Verizon, Prologis, Medtronic and Crimson are included in this Analyst Blog.
Top Stock Reports for Verizon, Prologis & Medtronic
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Verizon Communications Inc. (VZ), Prologis, Inc. (PLD) and Medtronic plc (MDT), as well as a micro-cap stock Crimson Wine Group, Ltd. (CWGL).
Is Vident International Equity Strategy ETF (VIDI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VIDI
Medtronic Keeps Capturing High-Growth Markets: Time to Buy MDT Stock?
by Urmimala Biswas
MDT stock breaking above its 200 and 50-day SMAs can be a piece of good news for investors, signaling an uptrend.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Company News for Aug 21, 2024
by Zacks Equity Research
Companies In The News Are: LLY, BA, AS, MDT.
Compared to Estimates, Medtronic (MDT) Q1 Earnings: A Look at Key Metrics (Revised)
by Zacks Equity Research
Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended July 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medtronic (MDT) Q1 Earnings Beat, Fiscal 2025 View Narrowed
by Zacks Equity Research
Medtronic (MDT) reports broad-based growth across all major segments, with strong gains in Cardiac Rhythm & Heart Failure, Structural Heart & Aortic, Cranial & Spinal Technologies and Diabetes businesses.
Markets Wait for Fed's July FOMC Minutes
by Zacks Equity Research
Markets Wait for Fed's July FOMC Minutes.
Dog Day of Summer: Right Now in the Stock Market
by Mark Vickery
It's this week -- today, precisely -- that best represents a typical late-summer stock market environment.
Compared to Estimates, Medtronic (MDT) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Medtronic (MDT) give a sense of how its business performed in the quarter ended July 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Medtronic (MDT) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Medtronic (MDT) delivered earnings and revenue surprises of 2.50% and 0.22%, respectively, for the quarter ended July 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy, Sell or Hold Medtronic (MDT) Before Q1 Earnings?
by Urmimala Biswas
Medtronic's (MDT) first-quarter profits might have been dented by higher costs and expenses originating from macro issues and geopolitical complexities. However, innovations may have boosted the top line.
Medtronic (MDT) Progresses in CGM With New Approval, Alliance
by Zacks Equity Research
The FDA approval for Medtronic's (MDT) Simplera CGM sets the stage for further regulatory submissions of the updated InPen smart insulin pen app.
Seeking Clues to Medtronic (MDT) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Medtronic (MDT) for the quarter ended July 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Masimo's (MASI) W1 Watch Gains FDA Nod for SafetyNet Connectivity
by Zacks Equity Research
The latest FDA clearance of Masimo's (MASI) W1 medical watch is likely to provide a continuous and accurate view of patients' health data.
IM Cannabis Corp. (IMCC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
IM Cannabis (IMCC) delivered earnings and revenue surprises of 79.76% and 12.07%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Medtronic (MDT) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
In the closing of the recent trading day, Medtronic (MDT) stood at $82.27, denoting a +1.33% change from the preceding trading day.
Abbott Up 7.7% Post Q2 Earnings: Should You Buy ABT Stock?
by Urmimala Biswas
Abbott's (ABT) strong growth projection for 2024 is an indication that the stock will be able to sustain the positive momentum through the rest of the year.